Tags

Type your tag names separated by a space and hit enter

Effects of one serving of mixed nuts on serum lipids, insulin resistance and inflammatory markers in patients with the metabolic syndrome.
Nutr Metab Cardiovasc Dis. 2011 Feb; 21(2):126-35.NM

Abstract

BACKGROUND AND AIMS

Knowledge of the effect of nut consumption on metabolic syndrome (MetS) components is limited. We assessed the effects of nut intake on adiposity, serum lipids, insulin resistance, and inflammatory biomarkers in patients with MetS.

METHODS AND RESULTS

In a randomized, parallel-group, 12-week feeding trial, 50 patients with MetS were given recommendations for a healthy diet with or without supplementation with 30 g/day of raw nuts (15 g walnuts, 7.5 g almonds and 7.5 g hazelnuts) (Nut and Control diet groups, respectively). Adiposity measures, serum lipids, insulin, Homeostasis Model Assessment (HOMA), interleukin-6 (IL-6) and other inflammatory biomarkers, and 48-h fecal fat were determined basally and at study's completion. Moderate weight loss, decreased adiposity, and lower blood pressure occurred similarly after both diets. The Control, but not the Nut diet, was associated with significant (P<0.05) reduction of LDL-cholesterol, with mean changes of -0.36 versus -0.13 mmol/L, respectively (between-group differences, P=0.154). The Nut diet reduced fasting insulin by 2.60 μU/mL (95% CI, -4.62 to -0.59) and HOMA-insulin resistance by 0.72 (-1.28 to -0.16) (P<0.05 versus Control diet; both). Among inflammatory markers, the Nut diet resulted in changes of median plasma IL-6 of -1.1 ng/L (-2.7 to -0.1; P=0.035 versus Control diet), but adjustment for weight loss attenuated the significance of the association. Stool fat decreased with the Control diet and slightly increased with the Nut diet (P<0.05 for between-group differences).

CONCLUSION

Patients with MetS show decreased lipid responsiveness but improved insulin sensitivity after daily intake of 30 g of mixed nuts.

Authors+Show Affiliations

Human Nutrition Unit, Hospital Universitari Sant Joan de Reus, IISPV, Rovira i Virgili University, Reus, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20031380

Citation

Casas-Agustench, P, et al. "Effects of One Serving of Mixed Nuts On Serum Lipids, Insulin Resistance and Inflammatory Markers in Patients With the Metabolic Syndrome." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 21, no. 2, 2011, pp. 126-35.
Casas-Agustench P, López-Uriarte P, Bulló M, et al. Effects of one serving of mixed nuts on serum lipids, insulin resistance and inflammatory markers in patients with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2011;21(2):126-35.
Casas-Agustench, P., López-Uriarte, P., Bulló, M., Ros, E., Cabré-Vila, J. J., & Salas-Salvadó, J. (2011). Effects of one serving of mixed nuts on serum lipids, insulin resistance and inflammatory markers in patients with the metabolic syndrome. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 21(2), 126-35. https://doi.org/10.1016/j.numecd.2009.08.005
Casas-Agustench P, et al. Effects of One Serving of Mixed Nuts On Serum Lipids, Insulin Resistance and Inflammatory Markers in Patients With the Metabolic Syndrome. Nutr Metab Cardiovasc Dis. 2011;21(2):126-35. PubMed PMID: 20031380.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of one serving of mixed nuts on serum lipids, insulin resistance and inflammatory markers in patients with the metabolic syndrome. AU - Casas-Agustench,P, AU - López-Uriarte,P, AU - Bulló,M, AU - Ros,E, AU - Cabré-Vila,J J, AU - Salas-Salvadó,J, Y1 - 2009/12/22/ PY - 2009/04/14/received PY - 2009/06/23/revised PY - 2009/08/12/accepted PY - 2009/12/25/entrez PY - 2009/12/25/pubmed PY - 2011/5/20/medline SP - 126 EP - 35 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 21 IS - 2 N2 - BACKGROUND AND AIMS: Knowledge of the effect of nut consumption on metabolic syndrome (MetS) components is limited. We assessed the effects of nut intake on adiposity, serum lipids, insulin resistance, and inflammatory biomarkers in patients with MetS. METHODS AND RESULTS: In a randomized, parallel-group, 12-week feeding trial, 50 patients with MetS were given recommendations for a healthy diet with or without supplementation with 30 g/day of raw nuts (15 g walnuts, 7.5 g almonds and 7.5 g hazelnuts) (Nut and Control diet groups, respectively). Adiposity measures, serum lipids, insulin, Homeostasis Model Assessment (HOMA), interleukin-6 (IL-6) and other inflammatory biomarkers, and 48-h fecal fat were determined basally and at study's completion. Moderate weight loss, decreased adiposity, and lower blood pressure occurred similarly after both diets. The Control, but not the Nut diet, was associated with significant (P<0.05) reduction of LDL-cholesterol, with mean changes of -0.36 versus -0.13 mmol/L, respectively (between-group differences, P=0.154). The Nut diet reduced fasting insulin by 2.60 μU/mL (95% CI, -4.62 to -0.59) and HOMA-insulin resistance by 0.72 (-1.28 to -0.16) (P<0.05 versus Control diet; both). Among inflammatory markers, the Nut diet resulted in changes of median plasma IL-6 of -1.1 ng/L (-2.7 to -0.1; P=0.035 versus Control diet), but adjustment for weight loss attenuated the significance of the association. Stool fat decreased with the Control diet and slightly increased with the Nut diet (P<0.05 for between-group differences). CONCLUSION: Patients with MetS show decreased lipid responsiveness but improved insulin sensitivity after daily intake of 30 g of mixed nuts. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/20031380/Effects_of_one_serving_of_mixed_nuts_on_serum_lipids_insulin_resistance_and_inflammatory_markers_in_patients_with_the_metabolic_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(09)00193-8 DB - PRIME DP - Unbound Medicine ER -